Reduced breakthrough symptom exacerbations in patients with biochemically controlled acromegaly switched from injected depot somatostatin receptor ligands to once-daily oral paltusotine in the PATHFNDR-1 clinical trial
Authors 0
- Author list not loaded yet.
Cited by 0 stored of 0
References 4
4 results